Tag: email

FORM 8.3

MINNEAPOLIS, June 25, 2025 (GLOBE NEWSWIRE) -- Jefferson Capital, Inc. (“Jefferson Capital”), a leading analytically driven purchaser and manager of charged-off and insolvency consumer accounts, today announced the pricing of its underwritten initial public offering of 10,000,000 shares of common stock at an initial public offering price of $15.00 per share. Jefferson Capital is offering 625,000 shares of common stock, and certain existing stockholders are offering 9,375,000 shares of common stock. In addition, the underwriters of the offering have a 30-day option to purchase from the selling stockholders up to 1,500,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. Jefferson Capital will not receive any proceeds from the sale of shares by the selling stockholders.

Plant-Based Daily Formula Updated in 2025 to Support Holistic Hearing Wellness and Lifestyle Resilience

SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- Biotechnology firm Iovance Biotherapeutics Inc. (NASDAQ: IOVA) announced a significant leadership transition, confirming the resignation of Chief Financial Officer Jean-Marc Bellemin, effective July 10, 2025. Mr. Bellemin, who assumed the CFO role in November 2020, is reportedly departing to pursue other endeavors, according to a regulatory filing. Bellemin’s exit comes at a tumultuous time, as the company is grappling with a recent commercial setback for its flagship drug, Amtagvi, and the specter of a class-action securities lawsuit.

SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit styled Ho v. Rocket Pharmaceuticals, Inc., et al., No. 3:25-cv-10049 (D. N.J.) has been filed and seeks to represent investors who purchased or otherwise acquired Rocket Pharmaceuticals securities between February 27, 2025 and May 26, 2025.

New York, June 25, 2025 (GLOBE NEWSWIRE) -- Eureka Acquisition Corp (the “Company”) (Nasdaq: EURK), a blank check company, today announced that in connection with its previously announced extraordinary general meeting in lieu of an annual general meeting of shareholders to be held on June 30, 2025, at 9:00 a.m., Eastern Time (the “Extraordinary General Meeting”), the Company has revised the contribution to its trust account and the terms and conditions in connection with the proposal to amend the Company’s current Charter (the “Charter Amendment Proposal”).

NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline.

TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psilocybin in mental health and well-being, is pleased to announce an update to its previously announced non-brokered private placement (the “Offering”) of common shares in the capital of the Company (the “Common Shares”).

Following a 198% sales surge in Q4, Hapbee added 191% revenue growth in Q1 2025 while reducing operating expenses by 62%

CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

TAMPA, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- Slide Insurance Holdings, Inc. (“Slide”) (Nasdaq: SLDE) today announced that, in connection with its previously completed initial public offering of its common stock, the underwriters have fully exercised their option to purchase an additional 3,600,000 shares of common stock from certain selling stockholders of Slide. The purchase of the additional shares closed on June 25, 2025, bringing the gross proceeds from the initial public offering to Slide and the selling stockholders to approximately $469.2 million. Slide will not receive any proceeds from the sale by such selling stockholders of the additional shares.